Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis.
Anne ConnollyPhoebe WallmanOlubanke DzahiniOliver HowesDavid M TaylorPublished in: Psychopharmacology (2024)
VMAT-2 inhibitors may have antipsychotic activity and may offer promise for treatment of psychosis with the potential for a reduced risk of TD.